Preethi Sundaram serves as the Chief Strategy Officer at Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neurological and epileptic diseases. In her role, Sundaram is responsible for overseeing the company's strategic direction, business development, and corporate growth initiatives. Her expertise and leadership have been instrumental in guiding Catalyst Pharmaceuticals through key phases of expansion and product development. Sundaram brings a wealth of experience to her position, having spent over two decades in the pharmaceutical and biotechnology industries. Prior to joining Catalyst Pharmaceuticals, she held various senior leadership roles at prominent companies, including positions in strategy, business development, and operations. Sundaram's career is marked by a series of successful collaborations and partnerships that have driven innovation and growth within the organizations she has served. Her strategic vision and ability to navigate complex market dynamics have earned her a reputation as a respected leader in the industry. Among her notable achievements, Sundaram has played a pivotal role in the successful launch and commercialization of several groundbreaking therapies. Her strategic oversight has been crucial in securing key partnerships and licensing agreements that have expanded Catalyst Pharmaceuticals' portfolio and strengthened its market position. Under her guidance, the company continues to pursue its mission of bringing life-changing treatments to patients with rare diseases, leveraging her deep industry knowledge and strategic acumen to drive sustainable growth and value creation.